SCHEMBL16663

SCHEMBL16663

O=S(=O)(c1ccccc1)c1ccc(-c2ccc(Br)cn2)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.42
AURKA O14965 3/20 0.41
HSD11B1 P28845 2/20 0.40
KMO O15229 2/20 0.39
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
LMNA P02545 2/20 0.38
KMT2A Q03164 2/20 0.38
CA2 P00918 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
HTR6 P50406 2/20 0.37
ABCC9 O60706 1/20 0.37
ABCC8 Q09428 1/20 0.37
KCNJ11 Q14654 1/20 0.37
KCNJ8 Q15842 1/20 0.37
APP P05067 1/20 0.37
KIF18A Q8NI77 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16990 0.85 POLB (0.44) RXFP1AURKAHSD11B1KMOALOX5AP
SCHEMBL16141 0.81 CA2 (0.48) AURKALMNAKMT2ACA2MAPT
SCHEMBL16810 0.79 HSD11B1 (0.57) HSD11B1FEN1CA2HTR6ABCC9
SCHEMBL16736 0.77 HSD11B1 (0.61) HSD11B1ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL16281 0.77 HSD11B1 (0.61) HSD11B1ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL12078980 0.77 HSD11B1 (0.61) HSD11B1ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL17437 0.71 POLB (0.53) HSD11B1HTR6ABCC9ABCC8KCNJ11
SCHEMBL15747736 0.70 NPC1 (0.53) ALDH1A1SMN1; SMN2
SCHEMBL15201063 0.70 GCK (0.45) RXFP1AURKALMNAKMT2ACA2
SCHEMBL12527297 0.70 ABCC9 (0.49) HSD11B1LMNAKMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 RXFP1 1927/4885AURKA 4394/4885HSD11B1 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.